Ac-225-PSMA-617 in mCRPC: an update

We now have some details from clinical trials of the radiopharmaceutical actinium-225-PSMA-617 (Ac-225-PSMA-617) in very advanced prostate cancer patients. … READ MORE …

Use of mpMRI and PSMA PET/CT to aid in salvage radiation decision-making

Because the success or failure of salvage radiation (SRT) hinges upon whether micrometastases are already systemic at the time of treatment, evidence that the cancer is still local improves the odds that SRT will be successful. … READ MORE …

Radio-guided surgery in the treatment of recurrent, initially localized prostate cancer

The re-treatment of patients with recurrent prostate cancer after initial, first-line treatment for what was initially diagnosed as localized disease can be complicated. Success (i.e., effective re-treatment with curative intent) in the re-treatment of such patients is often dependent on the ability to identify exactly where recurrence has occurred. … READ MORE …

Does Lu-177-PSMA-617 increase survival?

We have enthusiastically reported the encouraging outcomes of the early clinical trials of the radiopharmaceutical Lu-177-PSMA, most recently at this link. Based on reduction in PSA levels, it performs well. But medicines have no real benefit if all they do is treat PSA. We want medicines that increase survival. … READ MORE …

A new Lu-177-PSMA ligand has good results in a new study

Targeted nuclear medicine has shown some impressive outcomes in several small studies, mostly conducted in Germany. … READ MORE …

Gallium-68 PSMA PET/CT scans changed management in 39 percent of patients

The gold standard for the clinical relevance of any new test in the management of a specific disease is … Do the results of the test change the way a physician would previously have managed patients? … READ MORE …

Radio-guided salvage surgery for recurrent prostate cancer

A recent article (in German in Der Urologe) has discussed the early use of PSMA-radio-guided surgery (PSMA-RGS) for targeted resection of localized prostate cancer recurrence. … READ MORE …